Form 8-K - Current report:
SEC Accession No. 0001104659-26-084242
Filing Date
2026-07-16
Accepted
2026-07-16 16:05:45
Documents
12
Period of Report
2026-07-16
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2620677d1_8k.htm   iXBRL 8-K 39070
2 EXHIBIT 3.1 tm2620677d1_3-1.htm EX-3.1 6109
  Complete submission text file 0001104659-26-084242.txt   216165

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA otlk-20260716.xsd EX-101.SCH 3047
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE otlk-20260716_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE otlk-20260716_pre.xml EX-101.PRE 22380
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2620677d1_8k_htm.xml XML 3309
Mailing Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830
Business Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

EIN.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37759 | Film No.: 261180417
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)